New hope for stomach cancer: drug combo trial targets tough tumors
NCT ID NCT07332533
First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests a new drug combination (KN026 plus chemotherapy with or without enlonstobart) against the standard treatment for advanced HER2-positive stomach cancer that cannot be removed by surgery. About 490 adults will take part to see which approach shrinks tumors better and helps people live longer without the cancer growing. The goal is to find a more effective first-line therapy for this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.